A detailed history of Captrust Financial Advisors transactions in Amgen Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 583,626 shares of AMGN stock, worth $168 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
583,626
Previous 569,373 2.5%
Holding current value
$168 Million
Previous $178 Million 5.71%
% of portfolio
0.57%
Previous 0.58%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$309.38 - $337.38 $4.41 Million - $4.81 Million
14,253 Added 2.5%
583,626 $188 Million
Q2 2024

Aug 14, 2024

SELL
$262.75 - $319.31 $20 Million - $24.3 Million
-76,150 Reduced 11.8%
569,373 $178 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $64.8 Million - $78.3 Million
241,179 Added 59.65%
645,523 $184 Million
Q4 2023

Feb 14, 2024

BUY
$255.7 - $288.46 $972,938 - $1.1 Million
3,805 Added 0.95%
404,344 $116 Million
Q3 2023

Nov 14, 2023

BUY
$218.65 - $271.46 $289,711 - $359,684
1,325 Added 0.33%
400,539 $108 Million
Q2 2023

Aug 14, 2023

BUY
$214.27 - $253.37 $2.31 Million - $2.73 Million
10,775 Added 2.77%
399,214 $88.6 Million
Q1 2023

May 15, 2023

SELL
$225.79 - $275.2 $31,384 - $38,252
-139 Reduced 0.04%
388,439 $93.9 Million
Q4 2022

Feb 15, 2023

BUY
$229.03 - $291.01 $241,397 - $306,724
1,054 Added 0.27%
388,578 $102 Million
Q3 2022

Nov 16, 2022

BUY
$224.46 - $253.15 $11.1 Million - $12.6 Million
49,601 Added 14.68%
387,524 $87.3 Million
Q2 2022

Aug 23, 2022

BUY
$230.71 - $256.74 $77.9 Million - $86.7 Million
337,523 Added 84380.75%
337,923 $82.2 Million
Q2 2022

Aug 16, 2022

SELL
$230.71 - $256.74 $71.4 Million - $79.5 Million
-309,621 Reduced 99.87%
400 $97,000
Q1 2022

May 16, 2022

BUY
$219.27 - $242.57 $2.74 Million - $3.03 Million
12,497 Added 4.2%
310,021 $75 Million
Q4 2021

Feb 14, 2022

SELL
$198.88 - $227.6 $8.69 Million - $9.95 Million
-43,710 Reduced 12.81%
297,524 $66.9 Million
Q3 2021

Nov 16, 2021

BUY
$212.27 - $248.7 $4.8 Million - $5.63 Million
22,626 Added 7.1%
341,234 $72.6 Million
Q2 2021

Aug 16, 2021

BUY
$233.58 - $259.14 $5.95 Million - $6.6 Million
25,487 Added 8.7%
318,608 $77.7 Million
Q1 2021

May 17, 2021

BUY
$221.91 - $258.6 $4.66 Million - $5.43 Million
20,999 Added 7.72%
293,121 $72.9 Million
Q4 2020

Feb 16, 2021

BUY
$216.38 - $257.67 $4.96 Million - $5.91 Million
22,918 Added 9.2%
272,122 $62.6 Million
Q3 2020

Nov 17, 2020

BUY
$234.65 - $260.95 $2.71 Million - $3.01 Million
11,530 Added 4.85%
249,204 $63.6 Million
Q2 2020

Aug 14, 2020

BUY
$197.81 - $242.74 $4.75 Million - $5.83 Million
24,038 Added 11.25%
237,674 $60.6 Million
Q1 2020

May 15, 2020

BUY
$182.24 - $241.7 $3.18 Million - $4.21 Million
17,425 Added 8.88%
213,636 $42.3 Million
Q4 2019

Feb 14, 2020

BUY
$189.21 - $243.2 $32.6 Million - $41.9 Million
172,189 Added 716.8%
196,211 $47.1 Million
Q3 2019

Nov 14, 2019

BUY
$174.11 - $208.62 $43,353 - $51,946
249 Added 1.05%
24,022 $4.65 Million
Q2 2019

Aug 13, 2019

BUY
$166.7 - $195.41 $2.47 Million - $2.9 Million
14,828 Added 165.77%
23,773 $4.38 Million
Q1 2019

May 15, 2019

SELL
$180.87 - $203.88 $205,468 - $231,607
-1,136 Reduced 11.27%
8,945 $1.7 Million
Q4 2018

Feb 13, 2019

SELL
$178.4 - $208.25 $143,433 - $167,433
-804 Reduced 7.39%
10,081 $1.96 Million
Q3 2018

Nov 15, 2018

BUY
$185.29 - $208.89 $660,929 - $745,110
3,567 Added 48.74%
10,885 $2.26 Million
Q2 2018

Aug 13, 2018

BUY
$166.05 - $186.51 $4,151 - $4,662
25 Added 0.34%
7,318 $1.35 Million
Q1 2018

May 15, 2018

SELL
$169.43 - $198.0 $23,889 - $27,918
-141 Reduced 1.9%
7,293 $1.21 Million
Q4 2017

Feb 14, 2018

BUY
$168.79 - $188.59 $1.25 Million - $1.4 Million
7,434
7,434 $1.29 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $154B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.